Joven Garcia, MD
Internal Medicine · Palm Bay, FLNPI 1992865679
Payments from drug & device makers
Across 508 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Sanofi-aventis U.S. LLC$1K
- Lilly USA, LLC$758
- Novartis$594
- Amarin Pharma, Inc.$559
- Boehringer Ingelheim$432
- plus $4K from 25 others
What the payments were for
- Food & beverage$8,92299%
- Education$971%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 146 | $1,983 |
| Sanofi-aventis U.S. LLC | 59 | $1,163 |
| Lilly USA, LLC | 45 | $758 |
| Novartis | 30 | $594 |
| Amarin Pharma, Inc. | 32 | $559 |
| Boehringer Ingelheim | 21 | $432 |
| AstraZeneca | 24 | $412 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 21 | $404 |
| AbbVie(2 entities) | 19 | $388 |
| Pfizer | 18 | $352 |
| Johnson & Johnson | 21 | $342 |
| Exact Sciences | 13 | $333 |
| Amgen | 8 | $189 |
| Astellas Pharma US Inc | 7 | $152 |
| GSK | 7 | $139 |
| Bayer | 6 | $129 |
| Abbott | 6 | $127 |
| Insmed, Inc. | 3 | $77 |
| Phathom Pharmaceuticals, Inc. | 1 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $54 |
| Idorsia Pharmaceuticals US Inc | 3 | $46 |
| Esperion Therapeutics, Inc. | 2 | $46 |
| Biohaven Pharmaceuticals, Inc. | 2 | $42 |
| Cvrx, Inc. | 1 | $40 |
| Alnylam Pharmaceuticals Inc. | 2 | $38 |
| Merck | 2 | $35 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Eisai Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
How this compares
$9,019 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 358 | $520,843 |
| MounjaroTirzepatide | 102 | $166,468 |
| EliquisApixaban | 79 | $104,148 |
| JardianceEmpagliflozin | 66 | $91,363 |
| RybelsusSemaglutide | 39 | $74,730 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 53 | $55,592 |
| TradjentaLinagliptin | 45 | $50,089 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 75 | $47,017 |
| XareltoRivaroxaban | 31 | $46,986 |
| FarxigaDapagliflozin Propanediol | 38 | $46,496 |
| MyrbetriqMirabegron | 45 | $45,080 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $36,849 |
| JanuviaSitagliptin Phosphate | 29 | $33,873 |
| EntrestoSacubitril/Valsartan | 23 | $32,652 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $28,046 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,983 | $595,573397 claims |
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat, Spiriva Respimat, Glyxambi | $432 | $240,521254 claims |
| Lilly USA, LLCMounjaro, Trulicity | $758 | $184,296113 claims |
| PfizerEliquis | $352 | $104,14879 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Bevespi Aerosphere | $412 | $81,126115 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $139 | $56,39292 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,163 | $55,59253 claims |
| Johnson & JohnsonXarelto | $342 | $46,98631 claims |
| Astellas Pharma US IncMyrbetriq | $152 | $45,08045 claims |
| MerckJanuvia | $35 | $33,87329 claims |
| NovartisEntresto | $594 | $32,65223 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $404 | $17,82228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Palm Bay
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.